Dr. Martin Neuhaus is a corporate/M&A partner of Latham & Watkins in Germany and former Co-Chair of the German Corporate Department.
Mr. Neuhaus has extensive experience in domestic and cross-border M&A transactions, including public takeovers, private equity transactions, corporate restructurings, carve-outs, minority investments, and joint venture transactions.
He has advised multinational clients, such as Allianz, Axel Springer, Daimler, E.ON, IPIC/Aabar, Munich RE/ERGO, NOVA Chemicals, Novartis, RAG Stiftung, Scania, Syniverse, Tengelmann, and The Carlyle Group in some of their most significant transactions.
Mr. Neuhaus is listed as leading lawyer for M&A in Germany by IFLR1000 2017 and highly recommended for Corporate Law by clients (The Legal 500 Germany 2016). Additionally, he is recommended for M&A, Corporate Law, and Private Equity by JUVE 2016/2017.
He is a lecturer on cross-border M&A in the LLM program of the University of Münster. In addition, Mr. Neuhaus is a member of the German Corporate Law Association (VGR), the German-American Lawyer’s Association (DAJV), and a graduate of Harvard Law School Executive Education.
Dr. Neuhaus’ experience includes, among others, advising:
- Aabar Investments on its participation in Daimler, the establishment of an investment joint venture, ABAG, with Berndorf, Austria*
- Allianz in the divestiture of a 40% stake in Beiersdorf, in the (indirect) divestiture of ASL and Disko Group, the acquisition of manroland, and the divestiture of juris*
- Axel Springer in the acquisition and restructuring of PIN Group*
- Capcellence regarding its private equity activities for HSH Nordbank*
- Daimler in connection with its participation in TollCollect
- Deutsche Bank with respect to several EU cross-border mergers*
- Droege Capital in the divestiture of Madaus Pharma to Rottapharm*
- E.ON on various transactions including the divestiture of its Hungarian gas storage and trading business and E.ON Kernkraft in view of the contemplated split-off from E.ON Group
- IPIC on the acquisition of 70% in Ferrostaal, in compliance investigations on Ferrostaal and the subsequent unwinding of the Ferrostaal acquisition as well as on its participation in NOVA Chemicals*
- Mayne Pharma (Hospira), amongst others, in each of the acquisitions of Onkoworks, Biologici, PHT Pharma*
- NOVA Chemicals, amongst others, in the divestiture of its 50% stake in the global INEOS NOVA joint ventures to INEOS Group*
- Novartis in the (failed) takeover of Aventis, acquisition of Hexal, the divestiture of Arevipharma, and regarding post-M&A disputes*
- RAG Stiftung in the divestiture of a 25.01% stake in Evonik to CVC*
- Scania on takeover and corporate law aspects*
- SPP on the contemplated full ownership unbundling of eustream*
- Tengelmann Group on the divestiture of its supermarket business Kaiser’s Tengelmann and its e-stores business to EDEKA
- The Carlyle Group/Syniverse in the acquisition of global MACH Group and in the subsequent divestiture of MACH’s EEA data clearing and NRTRDE businesses*
*Matter handled prior to joining Latham